Silo Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Silo Pharma, Inc. (Nasdaq: SILO) on June 27, 2025, reporting a material event regarding its continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock price.
Material Changes
The Company received a Notification Letter from Nasdaq stating it failed to meet the minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This deficiency persisted for 30 consecutive business days between May 14, 2025, and June 26, 2025. Trading of the common stock continues without immediate interruption.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days, until December 24, 2025, to regain compliance.
- Remediation: To comply, the stock must close at or above $1.00 per share for 10 consecutive business days.
- Contingencies: If compliance is not met by the initial deadline, the Company may request an additional 180-day period if it meets other listing standards (e.g., market value of publicly-held shares) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- Risk of Delisting: Failure to qualify for or succeed in the second compliance period will result in a delisting determination, subject to appeal.
- Management Action: Management intends to monitor the bid price and may consider a reverse stock split to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of SILO stock relative to the $1.00 threshold.
- Monitor the Company's announcement regarding the intent to effect a reverse stock split before the December 24, 2025 deadline.
- Review the Company's market value of publicly-held shares to assess eligibility for a second compliance period if needed.
- Check for any subsequent filings regarding the status of the delisting appeal process if the initial cure period expires.